Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI-573 |
Synonyms | |
Therapy Description |
Dusigitumab (MEDI-573) is an antibody that targets IGF-1 and IGF-2, resulting in decreased IGF-mediated signaling and potentially leading to decreased tumor growth (PMID: 25193511). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI-573 | Dusigitumab | IGF1/2 Antibody 2 | Dusigitumab (MEDI-573) is an antibody that targets IGF-1 and IGF-2, resulting in decreased IGF-mediated signaling and potentially leading to decreased tumor growth (PMID: 25193511). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|